由于分析家给出了相互矛盾的评级和目标价格,喀罗斯治疗机构面临好坏参半的审查。 Keros Therapeutics faces mixed reviews as analysts give conflicting ratings and target prices.

Keros治疗公司(KROS)是一家生物制药公司,本周得到的评分不同。 Keros Therapeutics (KROS), a biopharmaceutical company, received contrasting ratings this week. HC Wainwright发布了40美元目标价的“买入”评级, Wedbush则维持了15美元目标的“中立”评级。 HC Wainwright issued a "buy" rating with a $40 target price, while Wedbush maintained a "neutral" rating with a $15 target. Keros正在开发KER-050,治疗心肌细胞综合症和宫膜纤维化综合症患者的低血细胞数。 Keros is developing KER-050 to treat low blood cell counts in patients with myelodysplastic syndromes and myelofibrosis. 股票在评级当日以10.28美元开放,市场上限为4.1698亿美元。 The stock opened at $10.28 on the day of the ratings, with a market cap of $416.98 million.